低危骨髓增生异常综合征患者接受促红细胞生成素刺激剂治疗的生存与生活质量:一项观察性队列研究
基于欧洲MDS登记处的非干预性前瞻性队列,纳入2008年1月1日至2019年7月1日期间诊断、血红蛋白<100 g/L的低危MDS患者,比较ESA暴露与未暴露者的生存和生活质量。倾向评分匹配后,ESA暴露组中位总生存44.9个月 vs 未暴露组34.8个月(HR 0.70,95%CI 0.59-0.83,p<0.0001)。未接受红细胞输注者生活质量显著优于接受输注者,与ESA暴露无关。
要点
- 低危MDS患者ESA暴露组中位总生存44.9个月,未暴露组34.8个月,绝对差10.1个月。
- 倾向评分匹配后ESA暴露组744例、未暴露组426例,HR 0.70(95%CI 0.59-0.83,p<0.0001)。
- 无论是否暴露ESA,未接受RBCT者HRQoL显著优于接受RBCT者。
核心结论
- 在低危MDS患者中,于规律输血治疗开始前或开始后早期启动ESA治疗可显著改善总生存。
- 避免红细胞输注与显著更好的健康相关生活质量相关。
研究设计与样本
- 欧洲MDS登记处为非干预性、纵向、真实世界登记研究,前瞻性纳入16个欧洲国家和以色列新诊断的>18岁低危(IPSS低危或中危-1)MDS患者。
- 分析限于2008年1月1日至2019年7月1日入组、血红蛋白<100 g/L的患者,末次数据删失为2021年12月31日。
- 每6个月记录治疗、输血和HRQoL,ESA治疗遵循当地指南;每次访视将患者分为无ESA或RBCT、仅ESA、ESA联合RBCT、仅RBCT四组。
- 按每6个月间期的ESA和RBCT状态进行纵向分析,采用倾向评分匹配;主要结局为中位总生存、无白血病生存和HRQoL。
- 研究注册于ClinicalTrials.gov,NCT00600860,正在进行中。
主要发现
- 2019年7月1日前诊断的2448例患者中,ESA未暴露组1265例、ESA暴露组1183例;男性1520例(62.1%),女性928例(37.9%);中位随访3.9年(IQR 1.6-6.5)。
- 应用纳入标准和倾向评分匹配后,ESA未暴露组426例、ESA暴露组744例。
- ESA暴露组中位总生存44.9个月(95%CI 40.2-50.5)vs ESA未暴露组34.8个月(95%CI 28.6-39.2),绝对差10.1个月(95%CI 2.2-18.0;HR 0.70,95%CI 0.59-0.83;p<0.0001)。
- 无论是否暴露ESA,未接受RBCT者HRQoL显著优于接受RBCT者(EQ-5d-3L指数评分线性混合效应模型RBCT系数-0.04,95%CI -0.06至0.03,p<0.0001;VAS线性混合效应模型-4.57,95%CI -6.02至-3.13,p<0.0001)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In our previous study on erythropoiesis-stimulating agent (ESA) treatment in lower risk myelodysplastic syndromes from the European MDS (EUMDS) Registry, we showed that patients treated with ESAs had longer survival compared with patients who receive red blood cell transfusion (RBCT). In this study, with a longer follow up time and more patients included, we aimed to assess long-term effects on survival and health-related quality of life (HRQoL) of exposure to ESAs with or without RBCT in patients with lower risk myelodysplastic syndromes. METHODS: The EUMDS Registry is a non-interventional, longitudinal, real-world registry prospectively enrolling newly diagnosed patients older than 18 years with lower risk (International Prognostic Scoring System low or intermediate-1) myelodysplastic syndromes from 16 European countries and Israel. The analysis was restricted to patients with haemoglobin concentrations less than 100 g/L enrolled between Jan 1, 2008, and July 1, 2019, with last censoring of data on Dec 31, 2021. Patient management was recorded every 6 months, including treatment, transfusions, and HRQoL. ESA treatment followed local guidelines. The patients were separated into four groups at each study visit: no ESA or RBCT, ESA only, ESA plus RBCT, and RBCT only. The data were analysed longitudinally over time according to ESA and RBCT status during each 6-month interval, using propensity score matching. The main outcomes were median overall survival and leukaemia-free survival, and HRQoL. This study is registered with ClinicalTrials.gov, NCT00600860, as is ongoing. FINDINGS: 2448 patients (the ESA-unexposed group [n=1265] and ESA-exposed group [n=1183]) were diagnosed before July 1, 2019; 1520 (62·1%) were male and 928 (37·9%) were female. Median follow-up time was 3·9 years (IQR 1·6-6·5). After applying eligibility criteria and propensity matching, there were 426 patients in the ESA-unexposed group and 744 patients in the ESA-exposed group. Median overall survival in the ESA exposed group was 44·9 months (95% CI 40·2-50·5) compared with 34·8 months (28·6-39·2) in the ESA unexposed group; the absolute difference was 10·1 months (95% CI 2·2-18·0; hazard ratio [HR] 0·70 [95% CI 0·59-0·83]; p<0·0001). Patients without RBCT in the presence or absence of ESA exposure maintained significantly better HRQoL than those with RBCT, irrespective of ESA exposure (linear mixed effect model of EQ-5d-3L index score, RBCT coefficient -0·04 [95% CI -0·06 to 0·03], p<0·0001; linear mixed effect model of VAS, -4·57 [-6·02 to -3·13], p<0·0001). INTERPRETATION: ESA treatment in patients with lower risk myelodysplastic syndromes significantly improves overall survival when started before or early after the onset of regular transfusion therapy. Avoiding RBCT is associated with significantly better HRQoL. FUNDING: H2020 European Research Council, Novartis Pharmacy B V Oncology Europe, Amgen, BMS/Celgene International, Janssen Pharmaceutica, Takeda Pharmaceuticals International, and Gilead Sciences.
引用
- Garelius HKG, Bagguley T, Taylor A, et al. Survival and quality of life in patients with lower risk myelodysplastic syndromes exposed to erythropoiesis-stimulating agents: an observational cohort study. Lancet Haematol. 2025. PMID: 39909656. doi:10.1016/S2352-3026(24)00350-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。